Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)

Long-term, Open-Labeled Extension Study of OCV-501 in Patients with Acute Myeloid Leukemia (Extension from Study 311-10-001)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221606

Enrollment

Registered

2011-10-05

Start date

2012-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

investigational material(s) Generic name etc : OCV-501 INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who completed the Study 311-10-001 and were judged that there was no relapse by any inspections in the end of the study. Patients who are capable of giving informed consent

Exclusion criteria

Exclusion criteria: Patients failed to discontinue the Study 311-10-001 even though patients met the discontinuation criteria. Patients who have participated in any other clinical trials , excluding the Study 311-10-001).

Design outcomes

Primary

Measure	Time frame
efficacy Recurrence based on the Response Evaluation Criteria by the International Working Group Conclusion of the Study	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026